✦ LIBER ✦

Bevacizumab for NSCLC: benefits weighed against risks

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The return of natalizumab: weighing bene

✍ Douglas Goodin 📂 Article 📅 2006 🏛 The Lancet 🌐 English ⚖ 51 KB

Balancing Risks against Benefits

📂 Article 📅 1969 🏛 Society for Science & the Public 🌐 English ⚖ 261 KB

PGI22 WEIGHING TREATMENT BENEFITS AGAINS

✍ FR Johnson; S Özdemir; C Mansfield; BE Sands; CA Siegel; SL Hass; DW Miller; TJ 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 67 KB

Primary prevention PVI for atrial fibril

✍ Gula, Lorne J.; Leong-Sit, Peter; Skanes, Allan C. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 442 KB

The transfusion dilemma – Weighing the k

✍ Refaai, Majed A.; Blumberg, Neil 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 251 KB

Weighing the risks and the benefits: A c

✍ Janine E Polifka; Elaine M Faustman; Nancy Neil 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 976 KB